-+ 0.00%
-+ 0.00%
-+ 0.00%

KDventures says Umecrine Cognition receives two US patent allowances for second-generation GAMSA compounds

PUBT·09/07/2026 07:11:58
Listen to the news
KDventures says Umecrine Cognition receives two US patent allowances for second-generation GAMSA compounds
  • KDventures said Umecrine Cognition received two USPTO Notices of Allowance covering second-generation GAMSA compounds GR3053 and GR3055.
  • The patents are expected to provide US New Chemical Entity protection through at least 2042.
  • The compounds broaden Umecrine Cognition’s platform in neurodegenerative diseases, alongside clinical candidate golexanolon.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.